Capricor Therapeutics (CAPR) Other financing activities (2012 - 2026)

Capricor Therapeutics' Other financing activities history runs 15 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• On a quarterly basis, Other financing activities rose 2820.64% year-over-year to $1.5 million in Q1 2026; TTM through Mar 2026 was $13.3 million, a 3044.13% increase from a year earlier, with the FY2025 full-year figure at $11.9 million, up 2534.18% from the prior year.
• Other financing activities retreated to $1.5 million in Q1 2026 per CAPR's latest filing, from $11.8 million in the prior quarter.
• Across five years, Other financing activities topped out at $11.8 million in Q4 2025 and bottomed at $1518.0 in Q3 2022.
• The 5-year median for Other financing activities is $26890.0 (2022), against an average of $988062.4.
• Across the five-year window, Other financing activities soared 8091.48% in 2024 and sank 94.26% in 2025, its largest moves.
• Year by year, Other financing activities stood at $26315.0 in 2022, then slumped by 88.5% to $3027.0 in 2023, then surged by 8091.48% to $247956.0 in 2024, then soared by 4651.44% to $11.8 million in 2025, then plunged by 87.52% to $1.5 million in 2026.
• Per Business Quant, the three latest CAPR Other financing activities figures stand at $1.5 million (Q1 2026), $11.8 million (Q4 2025), and $6950.0 (Q3 2025).